Merck Publishes Science Paper on Scalable Oral PCSK9 Inhibitor Manufacturing
RAHWAY, N.J., May 7, 2026 Merck announced the publication of a landmark scientific paper in the journal Science detailing...
Alzheimer’s Disease artificial intelligence ASCO 2026 Autoimmune Disease Bio-Pharma biologics biopharma Biotechnology Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Eli Lilly FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology oncology innovation Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine regulatory compliance targeted therapy
RAHWAY, N.J., May 7, 2026 Merck announced the publication of a landmark scientific paper in the journal Science detailing...
SANTA CRUZ, Calif., March 16, 2026 Unnatural Products has announced the successful closing of a $45 million Series B...
KANAGAWA, Japan, Dec. 17, 2025 — PeptiDream Inc. announced promising pre-clinical results for a novel oral dual IL-17A and...
